Structure-guided design of ultrapotent disruptive IgE inhibitors to rapidly terminate acute allergic reactions.

ABSTRACT:

Background

Anaphylaxis represents one of the most severe and fatal forms of allergic reactions. Like most other allergies, it is caused by activation of basophils and mast cells by allergen-mediated cross-linking of IgE bound to its high-affinity receptor, FcεRI, on the cell surface. The systemic release of soluble mediators induces an inflammatory cascade, rapidly causing symptoms with peak severity in minutes to hours after allergen exposure. Primary treatment for anaphylaxis consists of immediate intramuscular administration of adrenaline.

Objective

While adrenaline alleviates life-threatening symptoms of an anaphylactic reaction, there are currently no disease-modifying interventions available. We sought to develop potent and fast-acting IgE inhibitors with the potential

SUBMITTER: Pennington LF 

PROVIDER: S-EPMC8502201 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature